Country for PR: United Kingdom
Contributor: PR Newswire Europe
Wednesday, February 10 2021 - 11:01
AsiaNet
China National Medical Products Administration Approves MR-guided Focused Ultrasound To Treat Essential Tremor And Tremor-dominant Parkinson's Disease
HAIFA, Israel and MIAMI, Feb. 10, 2021 /PRNewswire-AsiaNet/ --

- Insightec is strategically positioned for expansion in the China market

Insightec® [http://www.insightec.com], a global healthcare company focused on 
creating the next generation of patient care, announced it received market 
approval by The National Medical Products Administration (NMPA), the Chinese 
agency for regulating drugs and medical devices (formerly the China Food and 
Drug Administration, or CFDA).

The approval for the Exablate® 4000 (Exablate Neuro) platform, will enable 
unilateral Focused Ultrasound treatment for patients living with debilitating 
tremor from Essential Tremor and Tremor-dominant Parkinson's Disease that has 
not responded to medications.  

"This achievement reflects positive momentum to bring Focused Ultrasound to 
movement disorder patients in China," commented Maurice R. Ferré MD, Insightec 
CEO and Chair of the Board of Directors. "We are committed to improving the 
quality of life of patients in China and worldwide with impactful therapeutic 
treatments."

MR-guided Focused Ultrasound (MRgFUS), also referred to as high-intensity 
Focused Ultrasound, delivers acoustic energy precisely to the Vim of the 
thalamus, considered to be responsible for tremor, to heat and ablate the 
tissue. The procedure does not require surgical incisions, implants or 
anesthesia. 

Nearly 60 leading neurosurgeons in medical centers around the globe are 
treating patients with hand tremor from Essential Tremor or Tremor-dominant 
Parkinson's Disease on a regular basis with the Exablate Neuro. Performed in a 
single session in an MRI suite, many patients experience immediate tremor 
relief with minimal side effects, returning home the same day.

"There are millions of people in China living with diminished function due to 
hand tremors from Essential Tremor and Tremor-dominant Parkinson's Disease," 
said Peng Qiu, Insightec China Country Manager. "Our elderly communities will 
now have an option that uses highly advanced technology that is less invasive."

Exablate Neuro has received marketing approval for Essential Tremor from the 
U.S. Food and Drug Administration (FDA) and regulatory bodies in Argentina, 
Australia, Canada, Chile, Europe, Israel, Japan, Kazakhstan, Korea, Russia, 
Taiwan and Turkey. 

Insightec's Exablate Body system is used in 20 hospitals across China to treat 
symptomatic uterine fibroids. 

About Insightec

Insightec is a global healthcare company creating the next generation of 
patient care by realizing the therapeutic power of acoustic energy. The 
company's Exablate® Neuro platform uses Focused Ultrasound, guided by MRI, to 
provide tremor relief to patients with Essential Tremor and Tremor-Dominant 
Parkinson's Disease. Research for future applications in the neuroscience space 
is underway in partnership with leading academic and medical institutions. 
Insightec is headquartered in Haifa, Israel, and Miami, with offices in Dallas, 
Shanghai and Tokyo. For more information, please visit: www.insightec.com. 

Forward-looking Statements

This document contains forward-looking statements regarding, among other 
things, plans, expectations, and future events. In some cases, forward-looking 
statements can be identified by the following words: "may," "can," "will," 
"could," "would," "should," "expect," "intend," "plan," "anticipate," 
"believe," "estimate," "predict," "project," "potential," "promise," 
"continue," "ongoing," or the negative of these terms. Forward-looking 
statements involve known and unknown risks, uncertainties and other important 
factors that could cause actual results to differ materially from what is 
expressed or implied by the statements. Any forward-looking statement is based 
on information available to INSIGHTEC as of the date of the statement. All 
written or oral forward-looking statements attributable to INSIGHTEC are 
qualified by this caution. INSIGHTEC does not undertake any obligation to 
update or revise any forward-looking statement to reflect any change in 
circumstances or in INSIGHTEC's expectations.

"Exablate," and "Exablate Neuro," as well as the "INSIGHTEC" logo, whether 
standing alone or in connection with the word " INSIGHTEC," are protected 
trademarks of INSIGHTEC.

Logo - https://mma.prnewswire.com/media/1120780/Insightec_Logo.jpg

Source: Insightec